CD8A and neoplasm: Of critical importance, a significantly higher level of CD3+/CD8+ tumor-infiltrating T lymphocytes (TILs) was observed in the mice treated with oHSV-D11mt compared to the mice treated with rHSVQ, suggesting that enhanced activation of adaptive T-cell immunity plays a key role in the observed enhanced therapeutic efficacy (Figure 6I–J).